BeOne Medicines
Ling Xue is an accomplished Executive Director of Portfolio and Program Management at BeiGene, with experience spanning from February 2015 to present, overseeing portfolio management and coaching junior team members. Prior roles include Senior Director and Director of Clinical Development, where responsibilities involved clinical trial strategy, regulatory submissions, and collaboration with clinical operations. Previously, Ling served as a Scientist III and II at Pharmacyclics, focusing on drug resistance mechanisms, and as a Senior Scientist at BioGenex, developing cancer biomarkers. Early career experiences include research at UC Berkeley, contributing to significant findings in cancer biology, culminating in a Ph.D. in Cancer Biology, alongside a master’s and bachelor’s degree in Biochemistry and Molecular Biology from Nankai University.
This person is not in any teams
This person is not in any offices
BeOne Medicines
36 followers
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.